Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, has announced that Rapha Capital BioVentures Fund I, LP (“RCBVFI”) led and closed on a new convertible note offering totaling $3 million. The note, which was funded in three tranches, will support the … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note Led by Rapha Capital”
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Closes on $3M Convertible Note”
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final design of its i/Blue Imaging System(TM) is on target to be demonstrated at the American Urology Association (“AUA”) Annual Meeting in September. In its 116th … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting”
Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stage and is expected to be completed in 2022, allows for white and blue light images to … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Poised to Establish New Standard in Bladder Cancer Visualization”
Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”) Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection Non-muscle-invasive … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization”
Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology”
Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark … Continue reading “BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Setting Stage for Strengthened Demand for Blue Light Cystoscopy”
Company’s i/Blue Imaging System(TM) is expected to be completed in 2022 The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence The bladder cancer market was valued at … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Making Advances in Bladder Cancer Treatment Through Proprietary Imaging Technology”
Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light … Continue reading “BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Innovative System Expected to Lead to More Successful Surgical Outcomes”
Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September”
